Charles M. Baum, M.D., Ph.D.

Dr. Baum has been President and Chief Executive Officer and Board Member of Mirati Therapeutics for the last eight years. Under his leadership, he transformed Mirati into a world class precision oncology company focused on translating drug discovery and research into novel therapeutics that target the genetic and immunologic drivers of various cancers. Prior to joining Mirati, Dr. Baum was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division and held multiple roles including Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including axitinib (Inlyta®), crizotinib (Xalkori®) and the approval of sunitinib (Sutent®). Prior to joining Pfizer, Dr. Baum oversaw the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) for the treatment of patients with advanced brain tumors. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications. Dr. Baum currently serves on the board of directors of BCTG Acquisition Corp. Dr. Baum holds an M.D. and a Ph.D. from Washington University School of Medicine and completed his post-graduate training at Stanford University.